The Leukemia & Lymphoma Society and Dana-Farber Cancer Institute to Bring Clinical Trials to Local Communities

Partnership Seeks to Accelerate Development of Innovative Therapies

LLS Applauds FDA's Approval of Lenalidomide for Patients with Relapsed or Refractory Mantle Cell Lymphoma

Approval marks first oral therapy for MCL patients, and a new option for patients with unmet medical need

The Leukemia & Lymphoma Society and Valor Biotherapeutics Partner to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients

Anti-CD20-Interferon Alpha Fusion Protein is a promising therapy for NHL patients resistant to standard therapy

News

Media Contacts

If you're a member of the media, you can direct all inquiries for The Leukemia & Lymphoma Society's (LLS's) South Central Texas Chapter to email theleukemialymphomasociety_txs@lls.org or call

San Antonio 210-998-5400 or 1-800-683-2458

Austin 512-491-6610 or 866-814-8113